TY - JOUR
T1 - Pancreatitis-diabetes-pancreatic cancer
T2 - Summary of an NIDDK-NCI workshop
AU - Andersen, Dana K.
AU - Andren-Sandberg, Åke
AU - Duell, Eric J.
AU - Goggins, Michael
AU - Korc, Murray
AU - Petersen, Gloria M.
AU - Smith, Jill P.
AU - Whitcomb, David C.
PY - 2013/11
Y1 - 2013/11
N2 - A workshop sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Cancer Institute (NCI) on Pancreatitis-Diabetes-Pancreatic Cancer focused on the risk factors of chronic pancreatitis (CP) and diabetes mellitus (DM) on the development of pancreatic ductal adenocarcinoma (PDAC). Sessions were held on (a) an overview of the problem of PDAC; (b) CP as a risk factor of PDAC; (c) DM as a risk factor of PDAC; (d) pancreatogenic, or type 3c, DM; (e) genomic associations of CP, DM, and PDAC; (f) surveillance of high-risk populations and early detection of PDAC; and (g) effects of DM treatment on PDAC. Recent data and current understandings of the mechanisms of CP- and DM-associated factors on PDAC development were discussed, and a detailed review of the possible risks of DM treatment on the development of PDAC was provided by representatives from academia, industry, and the Food and Drug Administration. The current status of possible biomarkers of PDAC and surveillance strategies for high-risk populations were discussed, and the gaps in knowledge and opportunities for further research were elucidated. A broad spectrum of expertise of the speakers and the discussants provided an unusually productive workshop, the highlights of which are summarized in the accompanying article.
AB - A workshop sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Cancer Institute (NCI) on Pancreatitis-Diabetes-Pancreatic Cancer focused on the risk factors of chronic pancreatitis (CP) and diabetes mellitus (DM) on the development of pancreatic ductal adenocarcinoma (PDAC). Sessions were held on (a) an overview of the problem of PDAC; (b) CP as a risk factor of PDAC; (c) DM as a risk factor of PDAC; (d) pancreatogenic, or type 3c, DM; (e) genomic associations of CP, DM, and PDAC; (f) surveillance of high-risk populations and early detection of PDAC; and (g) effects of DM treatment on PDAC. Recent data and current understandings of the mechanisms of CP- and DM-associated factors on PDAC development were discussed, and a detailed review of the possible risks of DM treatment on the development of PDAC was provided by representatives from academia, industry, and the Food and Drug Administration. The current status of possible biomarkers of PDAC and surveillance strategies for high-risk populations were discussed, and the gaps in knowledge and opportunities for further research were elucidated. A broad spectrum of expertise of the speakers and the discussants provided an unusually productive workshop, the highlights of which are summarized in the accompanying article.
UR - http://www.scopus.com/inward/record.url?scp=84887295824&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887295824&partnerID=8YFLogxK
U2 - 10.1097/MPA.0b013e3182a9ad9d
DO - 10.1097/MPA.0b013e3182a9ad9d
M3 - Article
C2 - 24152948
AN - SCOPUS:84887295824
SN - 0885-3177
VL - 42
SP - 1227
EP - 1237
JO - Pancreas
JF - Pancreas
IS - 8
ER -